



STEFAN J. KLAUBER  
DAVID A. JACKSON  
STEVE S. CHA  
VALETA A. GREGG, PH.D.\*  
STEPHEN GIGANTE  
LAWRENCE D. MANDEL\*  
CATHERINE ROSEMAN SMITH\*

\*BAR OTHER THAN N.J.  
\* COUNSEL

PATENT AGENTS

CHRISTINE E. DIETZEL, PH.D.  
MICHAEL A. YAMIN, PH.D.

SCIENTIFIC ADVISOR

VERONICA M. MALLON, PH.D.

KLAUBER & JACKSON  
ATTORNEYS AT LAW  
CONTINENTAL PLAZA  
411 HACKENSACK AVENUE  
HACKENSACK, NEW JERSEY 07601

PATENT, TRADEMARK AND  
COPYRIGHT CAUSES

(201) 487-5800

FACSIMILE: (201) 343-1684

WWW.KJILAW.COM

email: info@kjiplaw.com

February 1, 2002

Assistant Commissioner for Patents  
Washington, D.C. 20231

Attention: J. Ulm  
Primary Examiner

Re: U.S. Patent Application

Applicant(s): Jeffrey M. Friedman, et al.

Title: DB, THE RECEPTOR FOR LEPTIN, NUCLEIC ACIDS  
ENCODING THE RECEPTOR, AND USES THEREOF

Serial No.: 08/783,734


Filed: January 16, 1997

Docket No.: 600-1-162CP2

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the ASSISTANT COMMISSIONER OF PATENTS, WASHINGTON, DC 20231 on February 1, 2002.

Christine E. Dietzel, Reg. No. 37,309  
(Name of Registered Representative)

 2/1/02  
(Signature and Date)

**RESPONSE TO NOTICE IN SUBMISSION OF SEQUENCE LISTING  
AND PRELIMINARY AMENDMENT**

Sir:

Responsive to the Notice dated August 1, 2001, and in accordance with 37 CFR 1.821-1.825, Applicants submit herewith the following:

RECEIVED  
MAR 08 2002  
TECH CENTER 1600/2900

1600

SECTOR 1/3  
3700 1646




1. A substitute paper copy of a Sequence Listing for insertion into the Application as filed at the end of the Specification and prior to the Claims in compliance with the requirements of 37 C.F.R. 1.822 and/or 1.823.
2. A copy of the Sequence Listing in computer readable form (ASCII text), submitted on a 3½" floppy disk compatible with IBM format.
3. A statement in support of the filing and submission of a Sequence Listing in accordance with 37 CFR 1.821 - 1.825.
4. A copy of the Notice and Office Communication for Patent Applications containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures.
5. A Preliminary Amendment for entry into the file wrapper of the instant Application prior to further examination.
6. A check in the amount of \$1,960.00, covering the following:
  - (a) Fee for five-Month Extension of time under 37 CFR 1.17

The time set for this response is September 1, 2001.

Applicants request favorable consideration and entry of the Sequence Listing and Preliminary Amendment submitted herewith and further and favorable processing of the present Application.

Applicants hereby authorize that any charges in addition to the above authorized that relate to the filing and processing of the present Application in accordance with 37 CFR 1.16 and 1.17 may be charged to Deposit Account No. 11-1153. A duplicate copy of this letter is provided for this purpose.

Respectfully submitted,

  
Christine E. Dietzel  
Attorney for Applicant(s)  
Registration No. 37,309

CED/mb  
Enclosures





**UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

EXAMINER
----------

ART UNIT	PAPER NUMBER
----------	--------------

DATE MAILED:

*9/1/01*  
*002 2/102*

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

RECEIVED

AUG 03 2001

KLAUDER & JACKSON

DOCKETED CPI





UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office

Address: Commissioner of Patents and Trademarks  
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
---------------	-------------	-----------------------	---------------------

EXAMINER
----------

ART UNIT	PAPER NUMBER
----------	--------------

23

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application.

Commissioner of Patents

The instant specification and claims do not comply with 37 CFR § 1.822(o) which states that "[a] sequence that is made up of one or more noncontiguous segments of a larger sequence or segments from different sequences shall be presented as a separate sequence". Applicant needs to provide a **substitute computer readable form (CRF) copy of a "Sequence Listing"** which includes all of the sequences recited in the claims of the instant application and encompassed by these rules, a **substitute paper copy of that "Sequence Listing"**, an **amendment** directing the entry of that paper copy into the specification, and a **statement** that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. §§ 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d). The instant specification and/or claims will also need to be amended so that they comply with 37 C.F.R. § 1.821(d) which requires a reference to a particular sequence identifier (SEQ ID NO:) be made in the specification and claims wherever a reference is made to that sequence. For rules interpretation Applicant may call (703) 308-1123. See M.P.E.P. 2422.04.


Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to John D. Ulm whose telephone number is (703) 308-4008. The examiner can normally be reached on Monday through Friday from 9:00 AM to 5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler can be reached at (703) 308-6564.

Official papers filed by fax should be directed to (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

  
JOHN ULM  
PRIMARY EXAMINER  
GROUP 1800



Attachment for PTO-948 (Rev. 03/01, or earlier)  
6/18/01



The below text replaces the pre-printed text under the heading, "Information on How to Effect Drawing Changes," on the back of the PTO-948 (Rev. 03/01, or earlier) form.

**INFORMATION ON HOW TO EFFECT DRAWING CHANGES**

**1. Correction of Informalities -- 37 CFR 1.85**

New corrected drawings must be filed with the changes incorporated therein. Identifying indicia, if provided, should include the title of the invention, inventor's name, and application number, or docket number (if any) if an application number has not been assigned to the application. If this information is provided, it must be placed on the front of each sheet and centered within the top margin. If corrected drawings are required in a Notice of Allowability (PTOL-37), the new drawings **MUST** be filed within the **THREE MONTH** shortened statutory period set for reply in the Notice of Allowability. Extensions of time may **NOT** be obtained under the provisions of 37 CFR 1.136(a) or (b) for filing the corrected drawings after the mailing of a Notice of Allowability. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftsperson.

**2. Corrections other than Informalities Noted by Draftsperson on form PTO-948.**

All changes to the drawings, other than informalities noted by the Draftsperson, **MUST** be made in the same manner as above except that, normally, a highlighted (preferably red ink) sketch of the changes to be incorporated into the new drawings **MUST** be approved by the examiner before the application will be allowed. No changes will be permitted to be made, other than correction of informalities, unless the examiner has approved the proposed changes.

**Timing of Corrections**

Applicant is required to submit the drawing corrections within the time period set in the attached Office communication. See 37 CFR 1.85(a).

Failure to take corrective action within the set period will result in **ABANDONMENT** of the application.